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Abstract
Background: General supportive and preventive measures in the intensive care management of traumatic brain injury
(TBI) aim to prevent or limit secondary brain injury and optimize recovery. The aim of this survey was to assess and quantify
variation in perceptions on intensive care unit (ICU) management of patients with TBI in European neurotrauma centers.
Methods:We performed a survey as part of the Collaborative European NeuroTrauma Effectiveness Research in Traumatic
Brain Injury (CENTER-TBI) study. We analyzed 23 questions focused on: 1) circulatory and respiratory management; 2) fever
control; 3) use of corticosteroids; 4) nutrition and glucose management; and 5) seizure prophylaxis and treatment.
Results: The survey was completed predominantly by intensivists (n= 33, 50%) and neurosurgeons (n= 23, 35%) from 66
centers (97% response rate).
The most common cerebral perfusion pressure (CPP) target was > 60 mmHg (n= 39, 60%) and/or an individualized target
(n = 25, 38%). To support CPP, crystalloid fluid loading (n = 60, 91%) was generally preferred over albumin (n = 15, 23%),
and vasopressors (n = 63, 96%) over inotropes (n= 29, 44%). The most commonly reported target of partial pressure of
carbon dioxide in arterial blood (PaCO2) was 36–40 mmHg (4.8–5.3 kPa) in case of controlled intracranial pressure (ICP)
< 20 mmHg (n = 45, 69%) and PaCO2 target of 30–35 mmHg (4–4.7 kPa) in case of raised ICP (n = 40, 62%). Almost all
respondents indicated to generally treat fever (n = 65, 98%) with paracetamol (n = 61, 92%) and/or external cooling
(n = 49, 74%). Conventional glucose management (n = 43, 66%) was preferred over tight glycemic control (n = 18,
28%). More than half of the respondents indicated to aim for full caloric replacement within 7 days (n = 43, 66%)
using enteral nutrition (n = 60, 92%). Indications for and duration of seizure prophylaxis varied, and levetiracetam was
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mostly reported as the agent of choice for both seizure prophylaxis (n = 32, 49%) and treatment (n = 40, 61%).
Conclusions: Practice preferences vary substantially regarding general supportive and preventive measures in TBI
patients at ICUs of European neurotrauma centers. These results provide an opportunity for future comparative
effectiveness research, since a more evidence-based uniformity in good practices in general ICU management could
have a major impact on TBI outcome.
Keywords: Intensive care unit, Traumatic brain injury, Glucose, Nutrition, Fever, Ventilation, Blood pressure, Seizure,
Survey, Europe
Background
Traumatic brain injury (TBI) is one of the major causes of
trauma-related death and hospital admissions in Europe [1].
TBI is recognized as a complex heterogeneous syndrome
[2]. The higher vulnerability of this population is reflected
by higher mortality rates in patients with TBI compared
with non-head injured trauma patients [3]. Therefore, pa-
tients with (severe) TBI require specialized neurointensive
care (treatment) at an intensive care unit (ICU) [4].
Case fatality rates in severe TBI are high, ranging from
30% to 40% in unselected observational series [5]. Fur-
thermore, substantial between-country [1] and between-
center differences [3, 4, 6] in overall TBI mortality rates
exist which might be partly explained by differences in
treatment [7–9].
The key objectives of ICU TBI management are to
maintain general physiology and prevent secondary brain
injury. A number of brain-specific therapies, such as intra-
cranial pressure (ICP)-guided treatment or, less often,
brain-metabolic or cerebral vascular autoregulation-based
goals are employed both clinically or as the subject of clin-
ical research [10]. However, general support of the cardio-
vascular system, respiratory function, and nutritional or
metabolic needs must not be overlooked and could also
have a significant impact on outcome [11, 12]. Cerebral
metabolic control by seizure or fever management may
further contribute to better outcomes [2, 13–15]. At
present, optimal strategies for general management are
only partly established [16, 17]. This lack of robust evi-
dence may ultimately result in institutional or individual
variations in practice that may contribute to variances in
outcome.
The aim of this survey study was to assess variation in
ICU management perceptions of general supportive and
preventive care policies (including, for instance, circula-
tory and respiratory management) in patients with TBI
in European neurotrauma centers.
Methods
Participating centers
This study is part of the Collaborative European Neuro-
Trauma Effectiveness Research in Traumatic Brain In-
jury (CENTER-TBI) study that collects data on patient
characteristics, patient management, and outcomes in 68
centers from 20 countries across Europe and Israel [18].
All these centers were asked to complete a ‘Provider
Profiling Questionnaire’ [19]. The questionnaire items
used for this study (treatment at the intensive care) are
attached as Additional file 1.
Provider profiling questionnaire
The provider profiling questionnaire was developed in
several stages. First, literature was explored for evidence,
including guidelines and available surveys. Second, a
pilot study was conducted in 16 participating centers to
receive feedback, to determine ambiguity, and to detect
unexpected and missing values. Throughout all stages,
experts of various disciplines (neurosurgeons, intensi-
vists, neurologists, emergency department physicians, re-
habilitation physicians, medical ethicists, health care
economists, and epidemiologists) were asked for their
advice on the development of the questionnaire. Details
on the development, administration, and content of the
complete provider profiling questionnaires have been
published previously [19].
General supportive and preventive management
For the purpose of the current study, we focused on 23
questions specifically aimed at general ICU policies (Add-
itional file 1). Specifically, we focused on circulatory and re-
spiratory management, fever control, use of corticosteroids,
glucose and nutrition management, and seizure prophylaxis
and treatment. Most questions were multiple-choice, ex-
cept for two questions: the aim for caloric intake in TBI pa-
tients and the use of corticosteroids for other conditions.
Overall, the general policy of a center rather than the indi-
vidual treatment preference of the respondent was the
premise for completion of the questionnaire. General policy
is defined as: ‘the way the large majority of patients (> 75%)
with a certain indication would be treated’.
Statistical analysis
We used descriptive statistics (frequencies and percent-
ages) to present the data. Respondents could indicate
how frequently certain management strategies were
used (never 0–10%, rarely 10–30%, sometimes 30–70%,
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frequently 70–90%, and always 90–100%). The com-
bined numbers of respondents that indicated ‘fre-
quently’ and ‘always’ were interpreted as representing
the general policy of a center, in line with previous re-
ports [20, 21]. To describe center characteristics in
more detail we divided centers into higher (Austria,
Belgium, Denmark, Finland, France, Germany, Israel,
Italy, the Netherlands, Norway, Spain, Sweden, UK, and
Switzerland) versus relatively lower income countries
(Bosnia Herzegovina, Hungary, Latvia, Lithuania,
Romania, and Serbia), based on a 2007 report by the
European Commission [22]. Differences were assessed
for statistical significance using the Fisher’s exact test
without correction for multiple comparisons. We used
Statistical Package for Social Sciences (SPSS) version 21
[23] for descriptive analyses.
Results
Participating centers
Of the 68 neurotrauma centers participating in this
study, 66 (97%) centers completed the questions on gen-
eral supportive and preventive ICU management. The
questionnaire was predominantly completed by intensi-
vists (n = 33, 50%) and neurosurgeons (n = 23, 35%).
Other professionals that assisted in completion of the
questionnaire were administrative staff (n = 11, 17%),
neurologists (n = 5, 8%), anesthesiologists (n = 5, 8%),
and a trauma surgeon (n = 1, 2%).
The majority of centers had an academic affiliation
(n = 60, 91%). The majority of centers were designated
as level I trauma centers (n = 45, 69%), and a minority
as level II (n = 4, 6%), level III (n = 1, 2%), or no des-
ignation (n = 15, 23%). More than half of the centers
had a dedicated neuroICU (defined as an ICU that is
equipped to treat patients with neurological or neuro-
surgical injury) available (n = 39, 59%). The majority
of centers adopted a ‘closed’ ICU organization (the
intensivist is primarily responsible for the delivery of
care for patients at the ICU) (n = 43, 65%), followed
by a ‘mixed’ ICU organization (the admitting phys-
ician, e.g., neurosurgeon, is primarily responsible but
the care is provided by a intensivist) (n = 20, 30%),
and a minority adopted an ‘open’ ICU organization
(the admitting physician is primarily responsible for
care at the ICU) (n = 3, 5%). Centers indicated to
treat a median of 92 (interquartile range 52–160) pa-
tients with TBI at their ICU annually. Twenty-eight
centers (42%) reported to adhere to the 2007 Brain
Trauma Foundation (BTF) guidelines for the manage-
ment of patients with TBI at their ICU, and 21 cen-
ters (32%) reported having institutional guidelines that
were based on BTF guidelines. The center characteris-
tics and definitions are described in more detail in a
previous publication [19].
Circulatory and respiratory management
As part of circulatory management, the most frequently
mentioned cerebral perfusion pressure (CPP) targets
were > 60 mmHg (n = 39, 60%) and/or “individualized”
(n = 25, 38%). Most centers used crystalloids (n = 60,
91%) and/or vasopressors (n = 63, 96%) for CPP support;
inotropes (n = 29, 44%) were less frequently, but still
regularly, employed. Fifteen centers (23%) reported to
use albumin-containing solutions for volume expansion
(Additional file 2: Table S1).
In mechanically ventilated patients with TBI, initial
partial pressure of oxygen in arterial blood (PaO2)
goals of > 75 mmHg (10 kPa) (n = 29, 45%) and > 97.5
mmHg (13 kPa) (n = 29, 45%) were most commonly
cited as a treatment preference, with an initial arterial
oxygen saturation goal of > 95% (n = 56, 86%). In the
absence of raised ICP, most centers indicated a partial
pressure of carbon dioxide in arterial blood (PaCO2)
goal of 36–40 mmHg (4.8–5.3 kPa) (n = 45, 69%). In
the presence of raised ICP this shifted towards a lower
PaCO2 goal of 30–35 mmHg (4.0–4.7 kPa) (n = 40,
62%) (Fig. 1). The timing of tracheostomy in patients
with limited or slow neurological recovery varied sub-
stantially from within 1 week (n = 13, 20%) to between
1 and 2 weeks (n = 36, 55%) and more than 2 weeks
(n = 16, 25%) (Additional file 2: Table S1).
Relatively lower income countries more frequently
adopted lower oxygen saturation goals (> 90%) compared
with saturation targets > 95% which were favored by
higher income countries (n = 3/11, 27%, versus n = 2/55,
4%; p = 0.037) (Additional file 3: Table S6).
Fever control
In patients with TBI, the majority of centers indicated
that they routinely treat fever (n = 65, 98%). One center
(2%) reported they would only treat fever “sometimes”.
The preferred treatments were paracetamol (n = 61,
92%) and/or external cooling (n = 49, 74%). In contrast,
nonsteroidal anti-inflammatory drugs (NSAIDs) were
less commonly used (n = 29, 44%). Intravascular cooling
was also rarely used (n = 3, 5%) (Fig. 2) (Additional file 2:
Table S2).
Relatively lower income countries significantly
indicated the use of NSAIDs more often than higher
income countries (n = 11/11, 100%, versus n = 18/55,
33%; p = 0.000). Centers in higher income countries
indicated the use of paracetamol significantly more
frequently compared with relatively lower income
countries (n = 53/55, 96%, versus n = 8/11, 73%; p =
0.029). Intravascular cooling was more frequently
applied in the lower income group, although this
difference did not reach statistical significance
(Additional file 3: Table S7).
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Fig. 2 Type of fever treatment and corresponding percentage of centers that indicated they use this type of fever treatment never (in 0–10% of
cases), rarely (in 10–30% of cases), sometimes (in 30–70% of cases), frequently (in 70–90% of cases), or always (in 90–100% of cases). NSAID
nonsteroidal anti-inflammatory drug
Fig. 1 Mechanical ventilation thresholds with corresponding answer frequencies; 25–29 mmHg ≈ 3.3–3.0 kPa, 30–35 mmHg ≈ 4–4.7 kPa, 36–40
mmHg ≈ 4.8–5.3 kPa, 41–45 mmHg ≈ 5.5–6 kPa, 60 mmHg = 8 kPa, 75 mmHg = 10 kPa, 100 mmHg = 13 kPa. * No specific goal (n = 1), > 90
mmHg (n = 2); ^ > 96% (n = 2), > 97% (n = 1), 92–94% (n = 1). PaCO2 partial pressure of carbon dioxide in arterial blood, PaO2 partial pressure of
oxygen in arterial blood
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Use of corticosteroids
Corticosteroids were infrequently used for the primary
management of brain injury, although a few respondents
indicated that they used them “rarely” (n = 5, 8%), “some-
times” (n = 2, 3%), or “frequently” (n = 1, 2%). However,
corticosteroids were specifically used for vasopressor-
resistant hypotension (n = 21, 58%) and, to a lesser extent,
sepsis (n = 8, 22%) (Additional file 2: Table S3).
Primary use of corticosteroids was significantly more
frequently reported by lower income countries com-
pared with higher income countries (n = 4/11, 36%, ver-
sus n = 4/55, 7%; p = 0.023) (Additional file 3: Table S7).
Glucose and nutrition management
The majority of centers stated that their glucose man-
agement was protocolized (n = 50, 77%). Most centers
reported the correction of hyperglycemia as a primary
aim (n = 43, 66%) while a smaller number implemented
tight glycemic control (n = 18, 28%) (Additional file 2:
Table S4).
Most respondents aimed for full caloric replacement
within 7 days post-injury (n = 43, 66%). An open ques-
tion on the goals for caloric intake showed a high variety
in reported strategies as well as metrics used (kcal/day,
kcal/kg/day, and percentages). The enteral route was
preferred (n = 60, 92%). The timing of parenteral nutri-
tion was highly variable: centers were equally distributed
between “as soon as possible” (n = 13, 20%), “within 24 h
post-injury” (n = 13, 20%), “within 72 h post-injury” (n =
10, 15%), “within 7 days post-injury” (n = 17, 26%), and
“we do not have rules/guidelines for this” (n = 12, 19%)
(Additional file 2: Table S4).
Relatively lower income countries reported using the
parenteral route significantly more frequently compared
with higher income countries (n = 4/11, 36%, versus n =
1/55, 2%, p = 0.002) (Additional file 3: Table S7).
Seizure prophylaxis and treatment
There was little consensus regarding the use of prophy-
lactic antiepileptic drugs (for all indications). Most cen-
ters reported to use levetiracetam as the drug of choice
for both seizure prophylaxis and treatment (n = 32, 49%,
and n = 40, 61%), followed by phenytoin (n = 20, 31%,
and n = 32, 48%) (Fig. 3). In general, both the reported
duration of antiseizure prophylaxis and the criteria for
initiation of antiepileptic treatment varied considerably
(Additional file 2: Table S5).
The choice of agent varied with income, with levetirac-
etam being less commonly used for both seizure prophy-
laxis (n = 0/11 versus n = 32/55, 59%; p = 0.000) and
treatment (n = 1/11, 9%, versus n = 39/55, 71%; p =
0.000) in the lower income group versus higher income
countries, respectively. Instead, lower income countries
seemed to favor valproate or phenytoin compared with
higher income countries (n = 7/11, 64%, versus n = 14/
55, 26%; p = 0.029) (Additional file 3: Table S7).
Discussion
In this survey, we found varying degrees of consensus
between European neurotrauma centers with respect to
general supportive and preventive ICU management in
patients with TBI. Most variation was found in initial
PaO2 goals for mechanically ventilated patients, CPP
Fig. 3 Agents for seizure prophylaxis and treatment with corresponding percentage of centers that indicated that they never (in 0–10% of cases),
rarely (in 10–30% of cases), sometimes (in 30–70% of cases), frequently (in 70–90% of cases), or always (in 90–100% of cases) use the agent.
*Carbamazepine/phenobarbital, phenobarbital, benzodiazepines, no prophylaxis used in our hospital, carbamazepine (n = 3). ^Phenobarbital,
benzodiazepines, carbamazepine (n = 4), midazolam/diazepam, lorazepam
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targets, the timing of tracheostomy in unconscious patients,
nutritional targets, and seizure prophylaxis and treatment.
Large between-center variation was found in topics
that are not addressed in the recommendations of the
BTF guidelines (Additional file 4), suggesting the role
of guidelines in reducing variances in clinical practice.
International guidelines (BTF guidelines and guidelines
of the American College of Surgeons) do recommend
the use of normalized thresholds (e.g., normoglycemia,
normocapnia, and normothermia) in patients with TBI,
although this is not based on high-level evidence [16, 17].
Indeed, randomized controlled trials (RCTs) on these
topics are too limited in number to lead to high-level evi-
dence [10]. Considering CPP targets, the BTF guidelines
are unclear whether to use an optimum threshold of > 60
or > 70 mmHg (and a range of 50–70 mmHg in the pre-
vious BTF guidelines [24]). Despite this ambiguity, a
majority of respondents (60%) preferred a target CPP of >
60 mmHg. In addition, the current BTF guidelines added
that the CPP target might depend on the individual ce-
rebral autoregulatory status, reflected by 38% of respon-
dents who indicated to use an individualized target CPP.
The uniformity in reported CPP targets between income
groups also suggests that these concepts are widespread.
It may be that the willingness to individualize CPP in
patients with TBI reflects the growing trend for use of pre-
cision medicine [25], where therapies and therapy targets
are individualized to patient need, rather than used on a
“one size fits all” basis.
Marked variation was also found on topics where con-
sensus was expected based on high-level evidence from
RCTs or the recommendations in the BTF guidelines.
The use of steroids for the primary management of TBI
was reported by 13% of the respondents (one respondent
reported frequent use), but is against the advice of the
BTF guidelines and contradicts the prevailing evidence
from the CRASH study [26, 27]. However, use in the
majority of centers was for vasopressor dependence and/
or sepsis, a use in keeping with current guidelines for
the management of sepsis [28]. The use of albumin was
reported by 23% of the respondents, while the SAFE
study showed that albumin was associated with higher
mortality rates in patients with TBI [29]. It is difficult to
interpret the continued use of albumin for volume ex-
pansion as a lack of knowledge of the evidence, since
worse outcomes in the albumin-treated arm in SAFE-
TBI may have been the consequence of a hypotonic car-
rier causing elevated ICP [30], and well-informed clini-
cians may have used albumin that was isotonic or
corrected any accompanying hyponatremia. Finally, the
use of tight glycemic control was reported by 28% of re-
spondents, while the NICE-SUGAR and CGAO-REA
studies recommend using moderate instead of tight glu-
cose control in patients with TBI [31, 32].
On the other hand, we found consensus where vari-
ation was expected; a high number of centers indicated
they use antipyretic agents for the treatment of fever
when there is no consensus on the optimal choice of
agent and when their potentially deleterious side-effect
of CPP lowering is well known [33]. This suggests a
strong aversion amongst treating clinicians to allow pyr-
exia in patients with TBI. The choice of NSAIDs, despite
their well-known potentially harmful systemic side-effect
profile, as antipyretics in many centers probably also re-
flects this, although a continuous intravenous infusion
instead of intermittent NSAID dosing might improve
fever control (with relatively higher CPP) in neurocritical
care [34]. In addition, respondents indicated employing
below-normal PaCO2 goals (30–35 mmHg) in the pres-
ence of raised ICP in mechanically ventilated TBI patients.
This was unexpected given the BTF recommendation to
avoid prolonged hyperventilation. Furthermore, even pa-
tients in whom intracranial hypertension was not a con-
cern were ventilated to normal carbon dioxide tensions
showing a reluctance to use permissive ventilatory strat-
egies that have been shown to be effective in reducing
mortality in acute respiratory distress syndrome (ARDS)
patients [35].
Our results further suggest that respondents use TBI-
specific strategies instead of general strategies (as used
in the general critically ill patients) in the ICU. For ex-
ample, respondents indicated they frequently or always
treat fever since hyperthermia is associated with worse
outcomes in TBI [14, 33], whereas fever is often consid-
ered beneficial to some extent in critically ill patients
with infections [36].
We found some differences between relatively lower
versus higher income countries. It was striking that leve-
tiracetam was significantly more frequently reported by
higher income countries as an agent of choice for seiz-
ure prophylaxis and treatment, while valproate and
phenytoin were reported more frequently by lower in-
come countries, although high-level evidence in the lit-
erature on the agent of choice is lacking [37]. However,
there were no clear structural differences in manage-
ment overall, and this could not therefore be considered
an explanation for the treatment variation. Indeed, some
high-cost interventions, such as intravascular cooling
and parenteral nutrition, were more commonly used in
the lower income countries, suggesting that choices of
treatment options are not solely based on cost consider-
ations, but also reflect local clinical culture in different
institutions.
Our study has several strengths. To our knowledge,
this is the first survey that provides an overview of mul-
tiple components of general supportive or preventive
ICU management in patients with TBI. The survey was
developed in several stages with involvement of clinical
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experts of various disciplines and the response rate of
the survey was high (97%). However, this study also has
limitations, as the centers participating in the CENTER-
TBI study may still be a biased selection of European
centers with a specialist interest in the topic, or a large
engagement in research, or more expertise overall. In a
small number of centers, the questionnaire was com-
pleted by administrative staff (with no clinical expertise).
However, presumably this was in close collaboration
with a clinician considering the high number of clini-
cians that completed the survey, and clinical involve-
ment was encouraged throughout the survey. Other
limitations are inherent to surveys in that the results are
self-reported and are not confirmed by independent ob-
servations in daily practice and, therefore, represent
what the respondents ‘believe’ is clinical practice and
this may not, in fact, reflect reality. Another limitation is
that the survey questions represent generalizations and
do not include patient factors (such as demographics, la-
boratory results, or imaging), or very specific circum-
stances, while in clinical practice these details influence
clinicians’ judgement. In line with this, we did not spe-
cify time frames (for ventilation goals) and laboratory
values (for tight glucose control). Also, we asked about
general patients with TBI in the survey and did not spe-
cify adult or pediatric TBI.
Overall, the practice variation (and consensus) in gen-
eral ICU management we found might be explained by a
lack of evidence (or incomplete implementation of evi-
dence), by the use of individualized approaches, or by a
tension between general and TBI-specific strategies. We
presume that increased and more evidence-based uni-
formity in good practices in general ICU management
might improve outcome in TBI. In fact, general ICU
management is part of daily routine (e.g., temperature
measurements, laboratory results, and mechanical venti-
lation) and deviations are generally easily detected and
corrected. It is noteworthy that non-neurological com-
plications are frequent; in one report on TBI patients
these were more frequent (around 22%) than neuro-
logical complications (around 3%) [29]. Our survey
showed that future research on individualized manage-
ment is needed; a high number of respondents reported
individualized practices which implies a trend towards
precision medicine. In addition, the existence of practice
variation in general ICU management provides direction
to comparative effectiveness research (CER) analyses or
RCTs. As RCTs in the field of TBI have been disappoint-
ing [10], CER might be a promising approach to enhance
future knowledge on the effectiveness of general ICU
management, and understanding what process variances
occur, as we have attempted to do, is a critical starting
point. Hence, in the CENTER-TBI study we will evaluate
the effect of different ICU management practices on TBI
outcome (after case-mix correction); for example, the
difference in patient outcome between the 13 centers
that plan tracheostomy within 1 week, the 36 centers
that time tracheostomy between 1 and 2 weeks, and the
16 centers that delay tracheostomy longer than 2 weeks.
Conclusions
This study shows that general supportive and preventive
ICU management policies in TBI vary between European
neurotrauma centers. These findings stress the need for
continued knowledge transfer of existing evidence, fur-
ther research on optimized individualized management
(precision medicine) and, as we propose, comparative
effectiveness research.
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